Aigen Investment Management LP Buys Shares of 25,915 Agios Pharmaceuticals, Inc. $AGIO

Aigen Investment Management LP bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 4th quarter, HoldingsChannel reports. The firm bought 25,915 shares of the biopharmaceutical company’s stock, valued at approximately $705,000.

Several other large investors also recently added to or reduced their stakes in the stock. Bellevue Group AG grew its holdings in Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares in the last quarter. State Street Corp grew its holdings in Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after buying an additional 845,433 shares in the last quarter. Erste Asset Management GmbH grew its holdings in Agios Pharmaceuticals by 1.4% in the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after buying an additional 40,000 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP lifted its stake in shares of Agios Pharmaceuticals by 0.6% in the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after purchasing an additional 13,287 shares during the last quarter.

Agios Pharmaceuticals Stock Performance

AGIO opened at $29.46 on Monday. The stock’s 50-day moving average price is $29.34 and its 200 day moving average price is $28.51. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -4.06 and a beta of 0.59.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. The business’s revenue was up 137.7% on a year-over-year basis. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.2 earnings per share for the current year.

Analysts Set New Price Targets

AGIO has been the topic of several recent analyst reports. The Goldman Sachs Group upped their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. Citigroup upped their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. JPMorgan Chase & Co. decreased their price target on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Thursday. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Finally, Bank of America decreased their price target on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, May 29th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $40.89.

Insider Transactions at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 3,141 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $109,024.11. Following the transaction, the chief financial officer owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. This represents a 5.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,848.80. Following the transaction, the insider directly owned 49,306 shares in the company, valued at approximately $1,711,411.26. The trade was a 6.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 12,623 shares of company stock worth $438,144 in the last 90 days. Insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.